Mylotarg Phase IV Study In AML To Examine Combo Therapy For First-line Use
Executive Summary
Wyeth-Ayerst is planning a Phase IV study to evaluate Mylotarg in combination therapy for the treatment of patients recently diagnosed with CD33 positive acute myeloid leukemia, the company said.
You may also be interested in...
Oncologic Accelerated Approval Phase IV Studies For 7 Drugs To Be Reviewed
Accelerated approval Phase IV commitments for seven oncologic products will be reviewed at the March 12-13 meeting of FDA's Oncologic Drugs Advisory Committee
Oncologic Accelerated Approval Phase IV Studies For 7 Drugs To Be Reviewed
Accelerated approval Phase IV commitments for seven oncologic products will be reviewed at the March 12-13 meeting of FDA's Oncologic Drugs Advisory Committee
Wyeth Mylotarg Safety Profile Supports Use In Patients 60 - Advisory Cmte.
Wyeth's treatment for relapsed acute myeloid leukemia patients Mylotarg was recommended for accelerated approval in patients 60 years and older by FDA's Oncologic Drugs Advisory Committee March 17.